Literature DB >> 11083657

Comparative In vitro activities of daptomycin and vancomycin against resistant gram-positive pathogens.

D R Snydman1, N V Jacobus, L A McDermott, J R Lonks, J M Boyce.   

Abstract

The in vitro activity of daptomycin against 224 current gram-positive clinical isolates including vancomycin-resistant Enterococcus faecium (VREF), methicillin-resistant Staphylococcus aureus (MRSA), methicillin-resistant Staphylococcus spp. (MRSS), and penicillin-resistant Streptococcus pneumoniae (PRSP) was evaluated. The MICs at which 90% of isolates are inhibited for daptomycin and vancomycin, respectively, were as follows: MRSA, 1 and 2 microg/ml; MRSS, 1 and 4 microg/ml; PRSP, 1 and 0.5 microg/ml; and VREF, 2 and >64 microg/ml. Daptomycin was bactericidal against 82% of 17 VREF isolates. The antibacterial activity of daptomycin was strongly dependent on the calcium concentration of the medium. Daptomycin was active against all gram-positive cocci tested.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11083657      PMCID: PMC90222          DOI: 10.1128/AAC.44.12.3447-3450.2000

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  13 in total

1.  Rapid method for epidemiological evaluation of gram-positive cocci by field inversion gel electrophoresis.

Authors:  R V Goering; M A Winters
Journal:  J Clin Microbiol       Date:  1992-03       Impact factor: 5.948

2.  Activity of mersacidin, a novel peptide, compared with that of vancomycin, teicoplanin, and daptomycin.

Authors:  W W Niu; H C Neu
Journal:  Antimicrob Agents Chemother       Date:  1991-05       Impact factor: 5.191

3.  In vitro and in vivo activity of LY 146032, a new cyclic lipopeptide antibiotic.

Authors:  G M Eliopoulos; S Willey; E Reiszner; P G Spitzer; G Caputo; R C Moellering
Journal:  Antimicrob Agents Chemother       Date:  1986-10       Impact factor: 5.191

4.  In vitro activities of daptomycin, vancomycin, linezolid, and quinupristin-dalfopristin against Staphylococci and Enterococci, including vancomycin- intermediate and -resistant strains.

Authors:  M J Rybak; E Hershberger; T Moldovan; R G Grucz
Journal:  Antimicrob Agents Chemother       Date:  2000-04       Impact factor: 5.191

5.  Fluorescence indicates a calcium-dependent interaction between the lipopeptide antibiotic LY146032 and phospholipid membranes.

Authors:  J H Lakey; M Ptak
Journal:  Biochemistry       Date:  1988-06-28       Impact factor: 3.162

6.  Activities of daptomycin and teicoplanin against Staphylococcus haemolyticus and Staphylococcus epidermidis, including evaluation of susceptibility testing recommendations.

Authors:  D E Low; A McGeer; R Poon
Journal:  Antimicrob Agents Chemother       Date:  1989-04       Impact factor: 5.191

7.  Bactericidal activities of peptide antibiotics against multidrug-resistant Enterococcus faecium.

Authors:  N Mobarakai; J M Quale; D Landman
Journal:  Antimicrob Agents Chemother       Date:  1994-02       Impact factor: 5.191

8.  In vitro pharmacodynamic effects of concentration, pH, and growth phase on serum bactericidal activities of daptomycin and vancomycin.

Authors:  K C Lamp; M J Rybak; E M Bailey; G W Kaatz
Journal:  Antimicrob Agents Chemother       Date:  1992-12       Impact factor: 5.191

9.  Pharmacodynamics of daptomycin and vancomycin on Enterococcus faecalis and Staphylococcus aureus demonstrated by studies of initial killing and postantibiotic effect and influence of Ca2+ and albumin on these drugs.

Authors:  H Hanberger; L E Nilsson; R Maller; B Isaksson
Journal:  Antimicrob Agents Chemother       Date:  1991-09       Impact factor: 5.191

10.  Comparative in vitro activities of teicoplanin, daptomycin, ramoplanin, vancomycin, and PD127,391 against blood isolates of gram-positive cocci.

Authors:  D Shonekan; D Mildvan; S Handwerger
Journal:  Antimicrob Agents Chemother       Date:  1992-07       Impact factor: 5.191

View more
  22 in total

1.  Resistance studies with daptomycin.

Authors:  J A Silverman; N Oliver; T Andrew; T Li
Journal:  Antimicrob Agents Chemother       Date:  2001-06       Impact factor: 5.191

2.  Pharmacodynamics of S-3578, a novel cephem, in murine lung and systemic infection models.

Authors:  Shuichi Miyazaki; Kenichi Okazaki; Masakatsu Tsuji; Keizo Yamaguchi
Journal:  Antimicrob Agents Chemother       Date:  2004-02       Impact factor: 5.191

3.  In vitro activities of a new lipopeptide, HMR 1043, against susceptible and resistant gram-positive isolates.

Authors:  Pascale Bemer; Marie-Emmanuelle Juvin; Andre Bryskier; Henri Drugeon
Journal:  Antimicrob Agents Chemother       Date:  2003-09       Impact factor: 5.191

4.  Antistaphylococcal activity of LBM415, a new peptide deformylase inhibitor, compared with those of other agents.

Authors:  Kim Credito; Gengrong Lin; Lois M Ednie; Peter C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  2004-10       Impact factor: 5.191

5.  In vitro activity of daptomycin against gram-positive European clinical isolates with defined resistance determinants.

Authors:  Ad C Fluit; Franz-Josef Schmitz; Jan Verhoef; Dana Milatovic
Journal:  Antimicrob Agents Chemother       Date:  2004-03       Impact factor: 5.191

Review 6.  Telavancin: a novel semisynthetic lipoglycopeptide agent to counter the challenge of resistant Gram-positive pathogens.

Authors:  Biswadeep Das; Chayna Sarkar; Debasmita Das; Amit Gupta; Arnav Kalra; Shubham Sahni
Journal:  Ther Adv Infect Dis       Date:  2017-03-08

7.  Activity of daptomycin with or without 25 percent ethanol compared to combinations of minocycline, EDTA, and 25 percent ethanol against methicillin-resistant Staphylococcus aureus isolates embedded in biofilm.

Authors:  R Estes; J Theusch; A Beck; D Pitrak; Kathleen M Mullane
Journal:  Antimicrob Agents Chemother       Date:  2013-02-12       Impact factor: 5.191

Review 8.  Treatment options for vancomycin-resistant enterococcal infections.

Authors:  Peter K Linden
Journal:  Drugs       Date:  2002       Impact factor: 9.546

9.  In vitro and in vivo activities of tigecycline (GAR-936), daptomycin, and comparative antimicrobial agents against glycopeptide-intermediate Staphylococcus aureus and other resistant gram-positive pathogens.

Authors:  Peter J Petersen; Patricia A Bradford; William J Weiss; Timothy M Murphy; P E Sum; Steven J Projan
Journal:  Antimicrob Agents Chemother       Date:  2002-08       Impact factor: 5.191

Review 10.  Newer treatment options for skin and soft tissue infections.

Authors:  Murugan Raghavan; Peter K Linden
Journal:  Drugs       Date:  2004       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.